These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33125154)

  • 1. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
    Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
    Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
    Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
    Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.
    Lian X; Zhu C; Lin H; Gao Z; Li G; Zhang N; Cao B; Kang Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32022229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.
    Tian W; Hao S; Wang L; Chen Y; Li Z; Luo D
    Anticancer Drugs; 2022 Jan; 33(1):e622-e627. PubMed ID: 34407046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
    Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
    Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
    Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
    Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
    Niu Q; Liu J; Huang T; Su B; Zhang Y; Yuan X
    Oncol Res Treat; 2023; 46(1-2):11-25. PubMed ID: 36481773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Berton Giachetti PPM; Curigliano G
    Nat Rev Clin Oncol; 2024 Mar; 21(3):171-172. PubMed ID: 38114789
    [No Abstract]   [Full Text] [Related]  

  • 13. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
    Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
    Liu D; Kou F; Gong J; Wang Z; Zhang X; Li J; Li Y; Li J; Zhou J; Lu M; Wang X; Lu Z; Cao Y; Zou J; Zhu X; Xu R; Shen L
    Cancer Med; 2023 May; 12(9):10704-10714. PubMed ID: 37081722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
    Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
    Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.
    Dai J; Chen Y; Tang C; Wei X; Gong Y; Wei J; Gu D; Chen J
    Medicine (Baltimore); 2020 Jun; 99(25):e20809. PubMed ID: 32569228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
    Zhu W; Wu J; Cui M; Zhang L
    Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrotinib: First Global Approval.
    Blair HA
    Drugs; 2018 Nov; 78(16):1751-1755. PubMed ID: 30341682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
    BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.